Matthew Fedowitz, shareholder in the firm's Intellectual Property section, authored an article "Section 505(b)(2) new drug applications – untapped opportunities" which appeared in IAM Magazine.
We follow industry news and trends so you can stay ahead of the game. Subscribe to receive emails regarding policies and findings that impact you and your business.
Already a subscriber and want to update your preferences? Click here.